<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01432002</url>
  </required_header>
  <id_info>
    <org_study_id>HUG 07-153</org_study_id>
    <nct_id>NCT01432002</nct_id>
  </id_info>
  <brief_title>FDG-PET/CT for Simulation and Radiation Treatment Planning of Early Breast Cancer</brief_title>
  <official_title>Application of 18F-[FDG] PET/CT to Simulation and Planning of Radiotherapy (RT) for Breast Cancer. Definition of Target Volume for 3-D RT and for Partial Breast Irradiation (PBI) by IMRT Technique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is:

        -  to assess the potential benefits of 18F-[FDG] PET/CT and PET/MRI for operable breast
           cancer in order to define the size and location of the primary tumor, as well as
           axillary, supraclavicular and internal mammary lymph nodes.

        -  to apply the imaging results to the simulation and the radiation treatment planning and
           partial breast for 3-D radiation treatment and partial breast irradiation with intensity
           modulated radiation treatment (IMRT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pre-operative FDG PET/CT, and in option PET/IRM, are intended for women with histologically
      confirmed operable clinically node-negative breast cancer, in whom breast conserving and
      post-operative radiotherapy are planned.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Drawing of target volumes</measure>
    <time_frame>Up to 12 weeks after surgery</time_frame>
    <description>Compare the drawing of target volumes using the PET/CT, PET/IRM information, or without these imaging informations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlate the FDG PET/CT PET/IRM with surgical pathology findings</measure>
    <time_frame>Up to 12 weeks after surgery</time_frame>
    <description>Compare the pre-operative imaging information with histopathological description of the resected primary tumor, and with the extent of lymph node involvement.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Neoplasm</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Women with operable clinically node-negative breast cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed breast carcinoma

          -  Clinical stage T1-2 N0 M0

          -  Age &gt; 18 years

          -  Signed informed consent

        Exclusion Criteria:

          -  WHO performance index 3

          -  Premenopausal women without contraception

          -  Gestation

          -  Lactating

          -  Prior surgery or radiotherapy on the same breast

          -  Unable to understand study participation

          -  Bilateral breast cancer

          -  Prior CT thorax-abdomen and breast MRI within 4 months of interview

          -  Presence of electromechanical implant and/or body ferromagnetic material

          -  Previous history of renal insufficiency requiring dialysis and/or hospitalisation

          -  Ureum and/or creatinine within 2 weeks of interview above lab's reference limits

          -  History of contrast allergy

          -  Hyperthyroidy

          -  Claustrophobia.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Vinh-Hung, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiation Oncology, Geneva University Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiation oncology, Geneva University Hospitals</name>
      <address>
        <city>Geneva</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Bral S, Vinh-Hung V, Everaert H, De Coninck P, Storme G. The use of molecular imaging to evaluate radiation fields in the adjuvant setting of breast cancer: a feasibility study. Strahlenther Onkol. 2008 Feb;184(2):100-4. doi: 10.1007/s00066-008-1769-7.</citation>
    <PMID>18259702</PMID>
  </reference>
  <reference>
    <citation>Vinh-Hung V, Everaert H, Lamote J, Voordeckers M, van Parijs H, Vanhoeij M, Verfaillie G, Fontaine C, Vees H, Ratib O, Vlastos G, De Ridder M. Diagnostic and prognostic correlates of preoperative FDG PET for breast cancer. Eur J Nucl Med Mol Imaging. 2012 Oct;39(10):1618-27. Epub 2012 Jul 10.</citation>
    <PMID>22777335</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2011</study_first_submitted>
  <study_first_submitted_qc>September 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2011</study_first_posted>
  <last_update_submitted>May 12, 2017</last_update_submitted>
  <last_update_submitted_qc>May 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Geneva, Switzerland</investigator_affiliation>
    <investigator_full_name>Vincent Vinh-Hung</investigator_full_name>
    <investigator_title>Privat Docent</investigator_title>
  </responsible_party>
  <keyword>breast carcinoma</keyword>
  <keyword>FDG</keyword>
  <keyword>PET/CT</keyword>
  <keyword>PET/IRM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

